Filter Results:
(611)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 11 Jan 2017
- Research & Ideas
The Paradoxical Quest to Make Food Look 'Natural' With Artificial Dyes
chromate was used to make milk look creamier; and various poisonous ingredients were used to create bright colors for various candies, reportedly causing some children to fall ill or even die. Hisano highlights key dates in food coloring regulation history. The Food... View Details
Keywords: by Carmen Nobel
- 28 Jul 2015
- First Look
First Look: July 28, 2015
of Dublin, Ireland-based Elan Drug Technologies (EDT)-a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information about the planned merger, and details the funding options. The case... View Details
Keywords: Carmen Nobel
- 06 Apr 2015
- Research & Ideas
After Germanwings, More Attention Needed on Employee Mental Health
chronic work stress, while only 36 percent reported their employers provided adequate support to manage it. According to the National Institute of Mental Health, some 6.7 percent of American adults experience "major depressive disorder; antidepressants are the most... View Details
- 18 Jun 2001
- Research & Ideas
When In-House Research Isn’t Enough
system: Where are the best people and ideas in your field? "If you believe that knowledge is more and more globally distributed, chances are not all the best people work for you," he declared. Can you control the leakage of ideas? The patent system and... View Details
Keywords: by Jim Aisner
- 28 May 2014
- Research & Ideas
Building Histories of Emerging Economies One Interview at a Time
you are saving lives. So it has to have a humanitarian angle to it." (Cipla manufactures generic versions of a number of commonly prescribed medicines and is the world's largest manufacturer of the antiretroviral drugs that fight HIV and... View Details
Keywords: by Julia Hanna
- 08 Aug 2011
- Research & Ideas
The Death of the Global Manager
and its efforts to establish Humanitarian Assistance for Neglected Diseases (HAND), a corporate social responsibility program focused on treatments for diseases that typically affect too small a population to warrant the attention of drug... View Details
Keywords: by Julia Hanna
- 03 Apr 2007
- First Look
First Look: April 3, 2007
drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics—jointly affecting all R&D... View Details
Keywords: Martha Lagace
- 16 Jul 2008
- Op-Ed
What Should Employers Do about Health Care?
frequently in search of a better deal, which has meant that their employees needed to switch as well. They have tried to pare back covered services, thrown up barriers to expensive drugs and treatments, and recently, begun to pass more... View Details
- 24 May 2011
- First Look
First Look: May 24
decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven organisation had grown into one of Europe's largest biotech firms by revenues. Their success was mainly founded on... View Details
Keywords: Sean Silverthorne
- 23 Apr 2014
- HBS Case
Are Electronic Cigarettes a Public Good or Health Hazard?
Drug Administration is proposing the first federal oversight of the product. The very fact users could control the amount of nicotine they ingested led to worry that e-cigarettes would cause smokers to take in more nicotine, rather than... View Details
- 25 May 2016
- Research & Ideas
How Consumers and Businesses are Reshaping Public Health
commercialization of important new drugs to the detriment of consumers. Interestingly, though, at public hearings, the AstraZeneca chief executive championed the interests of patients in opposing the proposed merger. Consumers worldwide... View Details
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
programs to an investment board comprising both insiders (senior GSK executives) and outsiders (including a venture capitalist and a biotech CEO). After a three-month review period, successful teams are awarded three years worth of investment funding. Because View Details
Keywords: by Carmen Nobel
- 09 Mar 2020
- Research & Ideas
Warring Algorithms Could Be Driving Up Consumer Prices
being in second place, it’s a pretty good place to be.” Consumers end up paying more To study how pricing algorithms affect competition, MacKay and Brown collected detailed pricing data from five large, multicategory retailers selling the same over-the-counter allergy... View Details
- 11 Aug 2003
- Research & Ideas
Cheap, Fast, and In Control: How Tech Aids Innovation
experimentation and are triggering fundamental changes in R&D processes and performance in such fields as integrated circuit design, automotive development, and pharmaceutical drug discovery. Computer modeling and simulation, rapid... View Details
Keywords: by Wendy Guild
- 11 May 2010
- First Look
First Look: May 11
rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark Levin moved the firm downstream away from research and towards View Details
Keywords: Martha Lagace
- 13 Jul 2009
- Research & Ideas
Diagnosing the Public Health Care Alternative
of its inadequate payments. In the end, the Democrats' health care reform will require drastic rationing of health care for the sick to control its costs. The government-controlled UK health care system points the way because it features, for example, the lowest uptake... View Details
- 03 Jul 2012
- Research & Ideas
HBS Faculty on Supreme Court Health Care Ruling
invasive surgery, radiation, and chemotherapy for cancer, for example) with drugs that can palliate and perhaps cure genetically-linked diseases. But like most new technologies, these are hugely expensive to develop, and initially, to... View Details
- 06 May 2008
- First Look
First Look: May 6, 2008
Fibrosis Foundation: Venture Philanthropy Funding for Biotech Harvard Business School Case 808-005 In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would... View Details
Keywords: Martha Lagace
- 17 Oct 2006
- First Look
First Look: October 17, 2006
founded by a young venture capitalist and a university professor to exploit recombinant DNA technology. Thirty years and more than $300 billion in investments later, only a handful of biotech firms have matched Genentech's success or even shown a profit. No avalanche... View Details
Keywords: Sean Silverthorne
- 12 Jul 2006
- Research & Ideas
Competition the Cure for Healthcare
the various actors in the system are not designed around value, nor is competition reinforcing improvements in value. For example, let's take the prescription drug benefit, the big reform of today that everyone is talking about. This is... View Details